{"id":11791,"date":"2026-10-30T20:33:28","date_gmt":"2026-10-30T17:33:28","guid":{"rendered":"https:\/\/www.ortaakarsu.net\/?page_id=11791"},"modified":"2026-10-30T20:33:28","modified_gmt":"2026-10-30T17:33:28","slug":"coumadin-5-mg-english","status":"publish","type":"page","link":"https:\/\/www.ortaakarsu.net\/?page_id=11791","title":{"rendered":"Warfarin (Coumadin 5 mg): INR, Food and Interaction Safety"},"content":{"rendered":"<h2>Warfarin and the 5 mg tablet<\/h2>\n<p>Coumadin is a brand of warfarin sodium, a vitamin K antagonist anticoagulant. The archived US Coumadin information confirms the 5 mg oral tablet identity. Current clinical precautions here are also checked against US warfarin sodium tablet information revised in June 2026. Brand availability and tablet appearance vary between countries; this is not a claim that the Coumadin brand is marketed everywhere.<\/p>\n<p>Warfarin is used to prevent or treat specified blood clots and thromboembolic complications, including in selected people with atrial fibrillation or replacement heart valves. The 5 mg strength is not a standard daily dose for everyone. Treatment is individualised using the INR blood test, which reflects the anticoagulant response.<\/p>\n<h2>Monitoring, food and everyday precautions<\/h2>\n<p>Regular INR testing is essential. A new prescription, an acute illness or a substantial dietary change may mean the anticoagulation service needs to reassess monitoring. Vitamin K-containing foods can remain part of a balanced diet; consistency is more useful than suddenly eliminating vegetables. Starting vitamin supplements, herbal products or major dietary changes without discussing them can alter control.<\/p>\n<p>Excessive alcohol and binge drinking can increase risk. Tell a pharmacist before buying painkillers or supplements, and tell the dentist or surgeon about warfarin before procedures. Bring the current medicine list and anticoagulation record to appointments. Do not independently adjust the dose in response to a single symptom or another person\u2019s INR target.<\/p>\n<h2>Bleeding, interactions and pregnancy<\/h2>\n<p>Major or fatal bleeding is the central warning. Seek urgent help for persistent bleeding, black stools, blood in vomit, a major head injury, severe unexplained headache or new weakness. Painful purple skin lesions or unexpectedly painful, discoloured toes also need prompt assessment.<\/p>\n<p>Antibiotics, antifungals, NSAIDs, antiplatelets, many other medicines and some herbal products can affect anticoagulation or add bleeding risk. The interaction may require closer INR monitoring rather than a blanket ban on every combination. Warfarin can seriously harm a fetus; pregnancy requires urgent specialist review, with a narrow US-labelled exception for certain high-risk mechanical-valve patients. Breastfeeding decisions are individualised, with infant observation for bruising or bleeding.<\/p>\n<h2>Sources<\/h2>\n<ul>\n<li><a href=\"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/009218s017lbl.pdf\" rel=\"noopener\">Coumadin: archived FDA prescribing information confirming oral 5 mg tablets<\/a> \u2014 Historical brand label revised May 2017; used for brand\/form identity, not claimed latest safety label<\/li>\n<li><a href=\"https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=8cd0e744-b499-4344-b1db-59f85950e169\" rel=\"noopener\">Warfarin sodium tablets: current US prescribing information<\/a> \u2014 Taro US prescribing information revised June 2026<\/li>\n<li><a href=\"https:\/\/www.nhs.uk\/medicines\/anticoagulants\/considerations\/\" rel=\"noopener\">NHS: Anticoagulant medicines, considerations<\/a> \u2014 Current patient guidance checked 30 October 2026<\/li>\n<\/ul>\n<p>Source check: <time datetime=\"2026-10-30\">30 October 2026<\/time>. This date records a check of published sources, not an independent clinical review. The current leaflet for your own product and advice from a qualified healthcare professional take priority for personal treatment.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Coumadin is a warfarin brand. This oral-tablet summary explains INR monitoring, dietary consistency, bleeding risks and current warfarin precautions.<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-11791","page","type-page","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=\/wp\/v2\/pages\/11791","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=11791"}],"version-history":[{"count":1,"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=\/wp\/v2\/pages\/11791\/revisions"}],"predecessor-version":[{"id":11852,"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=\/wp\/v2\/pages\/11791\/revisions\/11852"}],"wp:attachment":[{"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=11791"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}